Profile Details

Create Project

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Hire Dr. Sekhar K.

United States

Experience in life sciences research and established problem solver

Profile Summary

Solved over 20 crowd challenges through Innocentive.com and Idea Connection. Experienced in drug discovery and target identification. I have Ph.D. in chemistry and worked in the field of life sciences for over 30 years. Published over 60 research papers in top journals.

Subject Matter Expertise

• ☆ Biochemistry
• ☆ Publishing
• ☆ Drug Discovery
• ☆ Drug Target Identification

Services

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Writing Technical Writing, General Proofreading & Editing

Research Scientific and Technical Research

Consulting Scientific and Technical Consulting

Data & AI Image Analysis

Product Development Concept Development

Work Experience

Staff Scientist

Vanderbilt University

September 2020 - Present

Scientist

Vanderbilt University Medical Center

January 1990 - January 2025

Education

Ph.D., Chemistry

Gulbarga University

August 1984 - August 1989

Ph.D. (Chemistry)

Gulbarga University

1984 - 1989

Certifications

• Certification details not provided.

Publications

PREPRINT

Konjeti R. Sekhar, Michael L. Freeman (2026). Data from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2026). Supplementary Data Legends from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2026). Supplementary Table S1 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2026). Supplementary Table S2 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2026). Supplementary Table S3 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2025). Supplementary Data Legends from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2025). Supplementary Table S1 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2025). Supplementary Table S2 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2025). Supplementary Table S3 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Data from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Supplementary Data Legends from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Supplementary Data Legends from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Supplementary Table S1 from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Supplementary Table S1 from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Supplementary Table S2 from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Supplementary Table S2 from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Supplementary Table S3 from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2024). Supplementary Table S3 from Nucleophosmin plays a role in repairing DNA damage and is a target for cancer treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Data from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Supplementary Data Legends from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Supplementary Data Legends from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Supplementary Table S1 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Supplementary Table S1 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Supplementary Table S2 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Supplementary Table S2 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Supplementary Table S3 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Konjeti R. Sekhar, Michael L. Freeman (2023). Supplementary Table S3 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment .

Baechle JJ, Hanna DN, Sekhar KR, Rathmell JC, Rathmell WK, Baregamian N(2021). Multiplatform Computational Analysis of Mast Cells in Adrenocortical Carcinoma Tumor Microenvironment .

Baechle JJ, Hanna DN, Konjeti SR, Rathmell JC, Rathmell WK, Baregamian N(2021). Multiplatform Integrative Analyses of Immunosuppressive Signatures in Cortisol-secreting Adrenocortical Carcinoma .

JOURNAL ARTICLE

Konjeti R. Sekhar, Michael L. Freeman (2023). Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment . Cancer Research.

Naira Baregamian, Konjeti R. Sekhar, Evan S. Krystofiak, Maria Vinogradova, Giju Thomas, Emmanuel Mannoh, Carmen C. Solórzano, Colleen M. Kiernan, Anita Mahadevan-Jansen, Naji Abumrad, et al. (2023). Engineering functional 3-dimensional patient-derived endocrine organoids for broad multiplatform applications . Surgery.

Baechle JJ, Hanna DN, Sekhar KR, Rathmell JC, Rathmell WK, Baregamian N(2021). Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma . Journal of cellular and molecular medicine.

Baechle JJ, Hanna DN, Sekhar KR, Rathmell JC, Rathmell WK, Baregamian N(2021). Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment . Surgery.

Geri Traver, Konjeti R. Sekhar, Peter A. Crooks, Diane S. Keeney, Michael L. Freeman(2021). Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC . Cancer Letters. 500. p. 220--227. Elsevier {BV}

Konjeti R. Sekhar, Irina Budunova, Jian Wang, Michael L. Freeman, Austin N. Kirschner(2019). Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway . PLOS ONE. 14. (4). p. e0214670. Public Library of Science ({PLoS})

Cameron BD, Sekhar KR, Ofori M, Freeman ML(2018). The Role of Nrf2 in the Response to Normal Tissue Radiation Injury . Radiation research.

Traver G, Mont S, Gius D, Lawson WE, Ding GX, Sekhar KR, Freeman ML(2017). Loss of Nrf2 promotes alveolar type 2 cell loss in irradiated, fibrotic lung . Free radical biology & medicine.

Smith CA, Mont S, Traver G, Sekhar KR, Crooks PA, Freeman ML(2016). Targeting Enox1 in tumor stroma increases the efficacy of fractionated radiotherapy . Oncotarget.

Mont S, Davies SS, Roberts Second LJ, Mernaugh RL, McDonald WH, Segal BH, Zackert W, Kropski JA, Blackwell TS, Sekhar KR, et al.(2016). Accumulation of isolevuglandin-modified protein in normal and fibrotic lung . Scientific reports.

Penthala NR, Ketkar A, Sekhar KR, Freeman ML, Eoff RL, Balusu R, Crooks PA(2015). 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1) . Bioorganic & medicinal chemistry.

Sekhar KR, Freeman ML(2015). Nrf2 promotes survival following exposure to ionizing radiation . Free radical biology & medicine.

Penthala NR, Crooks PA, Freeman ML, Sekhar KR(2015). Development and validation of a novel assay to identify radiosensitizers that target nucleophosmin 1 . Bioorganic & medicinal chemistry.

Sekhar KR, Benamar M, Venkateswaran A, Sasi S, Penthala NR, Crooks PA, Hann SR, Geng L, Balusu R, Abbas T, Freeman ML, International journal of radiation oncology, biology, physics, 2014, vol. 89, no. 5, pp. 1106-1114 .

Venkateswaran A, Sekhar KR, Levic DS, Melville DB, Clark TA, Rybski WM, Walsh AJ, Skala MC, Crooks PA, Knapik EW, Freeman ML, Cancer research, 2014, vol. 74, no. 1, pp. 38-43 .

Venkateswaran A, Friedman DB, Walsh AJ, Skala MC, Sasi S, Rachakonda G, Crooks PA, Freeman ML, Sekhar KR, Investigational new drugs, 2013, vol. 31, no. 3, pp. 535-544 .

Sekhar KR, Reddy YT, Reddy PN, Crooks PA, Venkateswaran A, McDonald WH, Geng L, Sasi S, Van Der Waal RP, Roti JL, Salleng KJ, Rachakonda G, Freeman ML, Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, vol. 17, no. 20, pp. 6490-6499 .

Travis EL, Rachakonda G, Zhou X, Korhonen K, Sekhar KR, Biswas S, Freeman ML, Free radical biology & medicine, 2011, vol. 51, no. 6, pp. 1175-1183 .

Mukhopadhyay S, Sekhar KR, Hale AB, Channon KM, Farrugia G, Freeman ML, Gangula PR, Free radical biology & medicine, 2011, vol. 51, no. 3, pp. 619-625 .

Francis SH, Sekhar KR, Ke H, Corbin JD, Handbook of experimental pharmacology, 2011 .

Venkateswaran A, Reddy YT, Sonar VN, Muthusamy V, Crooks PA, Freeman ML, Sekhar KR, Bioorganic & medicinal chemistry letters, 2010, vol. 20, no. 24, pp. 7323-7326 .

Pruitt R, Sasi N, Freeman ML, Sekhar KR, Bioorganic & medicinal chemistry letters, 2010, vol. 20, no. 20, pp. 5997-6000 .

Rachakonda G, Sekhar KR, Jowhar D, Samson PC, Wikswo JP, Beauchamp RD, Datta PK, Freeman ML(2010). Increased cell migration and plasticity in Nrf2-deficient cancer cell lines . Oncogene.

Sekhar KR, Rachakonda G, Freeman ML, Toxicology and applied pharmacology, 2010, vol. 244, no. 1, pp. 21-26 .

Reddy YT, Sekhar KR, Sasi N, Reddy PN, Freeman ML, Crooks PA, Bioorganic & medicinal chemistry letters, 2010, vol. 20, no. 2, pp. 600-602 .

Geng L, Rachakonda G, Morré DJ, Morré DM, Crooks PA, Sonar VN, Roti JL, Rogers BE, Greco S, Ye F, Salleng KJ, Sasi S, Freeman ML, Sekhar KR, FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2009, vol. 23, no. 9, pp. 2986-2995 .

Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, Freeman ML, Chemical research in toxicology, 2008, vol. 21, no. 3, pp. 705-710 .

Brown SL, Sekhar KR, Rachakonda G, Sasi S, Freeman ML, Cancer research, 2008, vol. 68, no. 2, pp. 364-368 .

Sonar VN, Thirupathi Reddy Y, Sekhar KR, Sasi S, Freeman ML, Crooks PA, Bioorganic & medicinal chemistry letters, 2007, vol. 17, no. 24, pp. 6821-6824 .

Sekhar KR, Sonar VN, Muthusamy V, Sasi S, Laszlo A, Sawani J, Horikoshi N, Higashikubo R, Bristow RG, Borrelli MJ, Crooks PA, Lepock JR, Roti Roti JL, Freeman ML, Cancer research, 2007, vol. 67, no. 2, pp. 695-701 .

Gao L, Wang J, Sekhar KR, Yin H, Yared NF, Schneider SN, Sasi S, Dalton TP, Anderson ME, Chan JY, Morrow JD, Freeman ML, The Journal of biological chemistry, 2007, vol. 282, no. 4, pp. 2529-2537 .

Geng L, Cuneo KC, Cooper MK, Wang H, Sekhar K, Fu A, Hallahan DE, Angiogenesis, 2007, vol. 10, no. 4, pp. 259-267 .

Kim KW, Mutter RW, Cao C, Albert JM, Shinohara ET, Sekhar KR, Lu B, Molecular cancer therapeutics, 2006, vol. 5, no. 11, pp. 2659-2665 .

Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, Lu B, Cancer research, 2006, vol. 66, no. 20, pp. 10040-10047 .

Stacy DR, Ely K, Massion PP, Yarbrough WG, Hallahan DE, Sekhar KR, Freeman ML, Head & neck, 2006, vol. 28, no. 9, pp. 813-818 .

Cao C, Shinohara ET, Li H, Niermann KJ, Kim KW, Sekhar KR, Gleave M, Freeman M, Lu B, International journal of radiation oncology, biology, physics, 2005, vol. 63, no. 4, pp. 1228-1236 .

Hong F, Sekhar KR, Freeman ML, Liebler DC, The Journal of biological chemistry, 2005, vol. 280, no. 36, pp. 31768-31775 .

Bakin AV, Stourman NV, Sekhar KR, Rinehart C, Yan X, Meredith MJ, Arteaga CL, Freeman ML, Free radical biology & medicine, 2005, vol. 38, no. 3, pp. 375-387 .

Weeks JL, Blount MA, Beasley A, Zoraghi R, Thomas MK, Sekhar KR, Corbin JD, Francis SH, Methods in molecular biology (Clifton, N.J.), 2005, vol. 307, pp. 239-262 .

Geng L, Osusky K, Konjeti S, Fu A, Hallahan D, Journal of controlled release : official journal of the Controlled Release Society, 2004, vol. 99, no. 3, pp. 369-381 .

Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD, Molecular pharmacology, 2004, vol. 66, no. 1, pp. 144-152 .

Saha D, Sekhar KR, Cao C, Morrow JD, Choy H, Freeman ML, Cancer research, 2003, vol. 63, no. 20, pp. 6920-6927 .

Sekhar KR, Crooks PA, Sonar VN, Friedman DB, Chan JY, Meredith MJ, Starnes JH, Kelton KR, Summar SR, Sasi S, Freeman ML, Cancer research, 2003, vol. 63, no. 17, pp. 5636-5645 .

Sekhar KR, Yan XX, Freeman ML(2002). Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2 . Oncogene.

Sekhar KR, Spitz DR, Harris S, Nguyen TT, Meredith MJ, Holt JT, Gius D, Marnett LJ, Summar ML, Freeman ML, Guis D, Free radical biology & medicine, 2002, vol. 32, no. 7, pp. 650-662 .

Sekhar KR, Soltaninassab SR, Borrelli MJ, Xu ZQ, Meredith MJ, Domann FE, Freeman ML(2000). Inhibition of the 26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase . Biochemical and biophysical research communications.

Soltaninassab SR, Sekhar KR, Meredith MJ, Freeman ML(2000). Multi-faceted regulation of gamma-glutamylcysteine synthetase. Journal of cellular physiology.

Sekhar KR, Freeman ML(1999). Autophosphorylation inhibits the activity of gamma-glutamylcysteine synthetase . Journal of enzyme inhibition.

Sekhar KR, Freeman ML(1998). PEST sequences in proteins involved in cyclic nucleotide signalling pathways . Journal of receptor and signal transduction research.

Sekhar KR, Long M, Long J, Xu ZQ, Summar ML, Freeman ML(1997). Alteration of transcriptional and post-transcriptional expression of gamma-glutamylcysteine synthetase by diethyl maleate . Radiation research.

Sekhar KR, Meredith MJ, Kerr LD, Soltaninassab SR, Spitz DR, Xu ZQ, Freeman ML(1997). Expression of glutathione and gamma-glutamylcysteine synthetase mRNA is Jun dependent . Biochemical and biophysical research communications.

McDuffee AT, Senisterra G, Huntley S, Lepock JR, Sekhar KR, Meredith MJ, Borrelli MJ, Morrow JD, Freeman ML(1997). Proteins containing non-native disulfide bonds generated by oxidative stress can act as signals for the induction of the heat shock response. Journal of cellular physiology.

PATENT

CROOKS PETER A, YERRAMREDDY THIRUPATHI R, PENTHALA NARSIMHA R, FREEMAN MICHAEL L, KONJETI SEKHAR R(2009). INDOLE COMPOUNDS AND THEIR USE AS RADIATION SENSITIZING AGENTS AND CHEMOTHERAPEUTIC AGENTS .